β-Cryptoxanthin may act as an RXR ligand by metabolic conversion to retinoids in vivo via BCMO1, contributing to the improvement of NAFLD pathology through a PPAR-mediated mechanism of action involved in improving insulin resistance. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.